August 26, 2025- Terumo Corporation announced that the Company has entered into a definitive agreement dated August 23, 2025, with OrganOx Limited (“OrganOx”), a leading innovator in organ preservation devices, and its shareholders to acquire all outstanding shares of OrganOx. Upon completion of the transaction, OrganOx will become a wholly owned subsidiary of Terumo. The total transaction value is approximately USD 1.5 billion.
OrganOx’s liver perfusion system supplies oxygenated blood, medications and nutrients to the donor organ near body temperature, according to MedTech Dive. The device allows functional assessment of the organ to support the decision on whether to transplant. U.K.-based OrganOx launched the system in 2022 in the U.S.